AI Nose and Smell Language Model debut at SEMICON Taiwan 2025, bringing scent intelligence to the global semiconductor stage. Trainable, portable, cloud-connected AI Nose with SaaS model turns scent into insights for smart manufacturing SAN DIEGO, CALIFORNIA / ACCESS Newswire / September 8, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced it will showcase its AI Nose industrial module at SEMICON Taiwan 2025, held September ...

1H 2025 Kicks Of AI Nose's Growing Commercial Momentum with First Senior Care Revenue and New Strategic Partnerships AI Nose 90-Day Roadmap to Power 2H 2025, With First Multi-Year $2.1M Order and Traction Across Robotics, Semiconductors, and Smart Manufacturing Exhibit 99.1 Ainos Reports Second Quarter 2025 Financial Results SAN DIEGO, CA/ ACCESSWIRE/ August 13, 2025/ Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-driven scent digitization, today announced its financial r ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from____to____ Commission File No. 001-41461 AINOS, INC. (Exact name of registrant as specified in its charter) | TEXAS | 75-1974352 | | --- | --- | | (State or oth ...

For the transition period from____to____ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-41461 AINOS, INC. (Exact name of registrant as specified in its charter) | TEXAS | 75-1974352 | | --- | --- | | (State or ot ...

Ainos Q1 2025 Financial Results and Business Update [Q1 2025 Financial Highlights](index=1&type=section&id=Q1%202025%20Financial%20Highlights) Ainos reported a significant 412% year-over-year revenue increase in Q1 2025, driven by its AI Nose products, achieving a notable turnaround from a gross loss to a gross profit, while expanding AI Nose technology into robotics and semiconductor sectors and advancing its VELDONA® therapeutic program with key clinical trial approvals Q1 2025 vs Q1 2024 Key Financial Metrics | Metric | Q1 2025 | Q1 2024 | Change | | :--- | :--- | :--- | :--- | | Revenues | $106,207 | $20,729 | +412% | | Gross Profit (Loss) | $87,974 | ($6,025) | Turnaround to Profit | - The substantial revenue growth was primarily driven by sales of AI Nose products for elderly care under the Nisshinbo Micro Devices Inc. ("NISD") co-development project[3](index=3&type=chunk) - The company is expanding its AI Nose technology beyond healthcare, establishing strategic partnerships in the robotics and semiconductor manufacturing sectors[2](index=2&type=chunk)[3](index=3&type=chunk) - The VELDONA® therapeutics program advanced significantly, securing Taiwan Food and Drug Administration (TFDA) and Institutional Review Board (IRB) approvals for two separate clinical trials in Taiwan[2](index=2&type=chunk)[4](index=4&type=chunk) [Management Commentary](index=1&type=section&id=Management%20Commentary) Management highlighted the successful execution of their long-term strategy, emphasizing the commercial viability of AI Nose technology and its expansion beyond healthcare, noting key milestones in the VELDONA® therapeutics program and a disciplined financial approach that turned a gross loss into a profit, positioning the company for future growth [CEO Commentary](index=1&type=section&id=CEO%20Commentary) The CEO emphasized the strategic progress in Q1, highlighting the 412% revenue growth driven by AI Nose sales, detailing the expansion of AI Nose applications into robotics and industrial sectors through new partnerships, aligning with significant market growth projections, and noting key regulatory approvals for the VELDONA® program, reinforcing the company's commitment to innovation and shareholder value - The company is expanding the application of its AI Nose technology from its roots in healthcare into the robotics and industrial sectors through strategic collaborations[3](index=3&type=chunk) - Management cited significant market potential, with the global electronic nose market projected to grow from **$29.8 billion** in 2025 to **$76.5 billion** by 2032[3](index=3&type=chunk) - The VELDONA® program secured TFDA approval for a clinical trial targeting HIV oral warts and IRB clearance for a trial targeting primary Sjögren's syndrome[4](index=4&type=chunk) - The CEO positioned Ainos as a U.S.-based innovator pioneering digital scent to provide a missing layer of perception for the next generation of intelligent systems[4](index=4&type=chunk) [CFO Commentary](index=2&type=section&id=CFO%20Commentary) The CFO highlighted the financial benefits of the company's strategic shift, noting a 412% YoY revenue increase to $106,207 and a 32% reduction in cost of revenues, resulting in a strong turnaround to a gross profit of $87,974 from a gross loss in the prior year, and despite higher non-cash SG&A expenses, disciplined capital management maintained operational efficiency, with continued investment planned for R&D Q1 2025 Financial Performance Highlights | Metric | Q1 2025 | Q1 2024 | Change | | :--- | :--- | :--- | :--- | | Revenues | $106,207 | $20,729 | +412% | | Cost of Revenues | $18,233 | $26,754 | -32% | | Gross Profit (Loss) | $87,974 | ($6,025) | Turnaround | - The turnaround from gross loss to gross profit was attributed to the unique product composition of AI Nose sales and a decline in the cost of revenues[4](index=4&type=chunk) - Selling, general and administrative (SG&A) expenses increased due to non-cash share-based compensation[4](index=4&type=chunk) - Future strategy involves continued investment in R&D for AI Nose and clinical trials, while evaluating optimal financing and partnership opportunities[4](index=4&type=chunk) [Recent Business Developments](index=3&type=section&id=Recent%20Business%20Developments) During the first quarter of 2025, Ainos established several key strategic partnerships to expand the application of its AI Nose technology, notably with semiconductor leader Advanced Semiconductor Engineering, Inc. (ASE) and robotics firm ugo, Inc., also advancing its VELDONA® therapeutic program by securing regulatory approvals for two clinical trials in Taiwan and strengthening its intellectual property with a new patent in Japan - Formed a strategic partnership with ASE Chung Li, a key site of the world's leading semiconductor assembly and test provider, to deploy AI Nose in semiconductor manufacturing[5](index=5&type=chunk)[8](index=8&type=chunk) - Partnered with ugo, Inc., Japan's leading service robotics company, to integrate AI Nose into robots, with the initial installation successfully completed[6](index=6&type=chunk)[9](index=9&type=chunk) - Secured TFDA and IRB approvals for clinical trials of its VELDONA® formulation for treating HIV-related oral warts and primary Sjögren's syndrome[7](index=7&type=chunk) - Received a key invention patent in Japan for its oral interferon formulation, VELDONA®, for treating and preventing coronavirus infections[10](index=10&type=chunk) [Financial Statements](index=5&type=section&id=Financial%20Statements) The unaudited financial statements for the period ending March 31, 2025, detail the company's financial position and performance, with the balance sheet showing a decrease in total assets and total liabilities compared to year-end 2024, and the statement of operations highlighting a significant revenue increase and a shift from a gross loss to a gross profit, though the company still recorded a net loss for the quarter [Condensed Balance Sheets](index=5&type=section&id=Ainos%2C%20Inc.%20Condensed%20Balance%20Sheets) As of March 31, 2025, Ainos reported total assets of $26.4 million, down from $28.8 million at the end of 2024, primarily due to a decrease in cash and cash equivalents, while total liabilities slightly decreased to $13.2 million, and total stockholders' equity fell to $13.1 million from $15.5 million Balance Sheet Summary (Unaudited) | Account | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Total Current Assets | $3,050,992 | $4,337,808 | | **Total Assets** | **$26,353,076** | **$28,820,199** | | Total Current Liabilities | $1,523,467 | $3,954,944 | | **Total Liabilities** | **$13,231,424** | **$13,303,889** | | **Total Stockholders' Equity** | **$13,121,652** | **$15,516,310** | - Cash and cash equivalents decreased from **$3.9 million** on December 31, 2024, to **$2.6 million** on March 31, 2025[16](index=16&type=chunk) [Condensed Statements of Operations](index=6&type=section&id=Ainos%2C%20Inc.%20Condensed%20Statements%20of%20Operations) For the three months ended March 31, 2025, Ainos reported revenues of $106,207, a 412% increase from the same period in 2024, achieving a gross profit of $87,974, a significant turnaround from a gross loss of $6,025 in the prior year, and despite this, the net loss remained relatively stable at $3.29 million, or ($0.21) per share, compared to a net loss of $3.31 million, or ($0.57) per share, in Q1 2024 Statement of Operations Summary (Unaudited) | Metric | Three months ended March 31, 2025 | Three months ended March 31, 2024 | | :--- | :--- | :--- | | Revenues | $106,207 | $20,729 | | Gross Profit (Loss) | $87,974 | ($6,025) | | Loss from Operations | ($3,162,871) | ($3,120,091) | | **Net Loss** | **($3,286,022)** | **($3,314,810)** | | Net Loss per Share | ($0.21) | ($0.57) | - Research and development expenses decreased to **$1.72 million** from **$2.08 million** in the prior-year period[18](index=18&type=chunk) - Selling, general and administrative expenses increased to **$1.53 million** from **$1.03 million** year-over-year[18](index=18&type=chunk)

Financial Performance - Revenues for fiscal year 2024 were $20,729, a significant decline from $122,112 in 2023, primarily due to lower sales of COVID-19 antigen rapid test kits [5]. - Cost of revenues decreased to $52,595 in 2024 from $375,845 in 2023, reflecting the reduced sales volume [6]. - Gross profit for 2024 was negative $31,866, an improvement from negative $253,733 in 2023, attributed to lower sales volume and reduced costs [7]. - Net loss attributable to common stock shareholders was $14,863,161 in 2024, compared to $13,770,549 in 2023 [11]. Operating Expenses - Total operating expenses increased to $13,809,338 in 2024 from $12,952,663 in 2023, driven by investments in AI Nose and VELDONA® development [8]. - Research and development expenses rose to $8,413,923 in 2024 from $7,317,388 in 2023, reflecting increased collaborative research and staffing costs [9]. - Selling, general and administrative expenses decreased to $5,395,415 in 2024 from $5,635,275 in 2023, mainly due to lower professional and public relations expenses [10]. Cash Position - As of December 31, 2024, cash and cash equivalents increased to $3,892,919 from $1,885,628 in 2023 [12]. Future Plans - Ainos plans to commence clinical studies for the second-generation Ainos Flora in H1 2025, aiming to establish leadership in the global POCT market [3]. - The company has received IRB approval for its clinical trial of VELDONA® in treating Sjögren's syndrome, with trials expected to begin in early 2025 [14].

Financial Performance - The company reported revenues of $20,729 for the year ended December 31, 2024, a decrease of 83% from $122,112 in 2023, primarily due to lower sales volume of COVID-19 Antigen Rapid Test Kits [263][264]. - The cost of revenues decreased to $52,595 in 2024 from $375,845 in 2023, reflecting a decline in sales volume of COVID-19 Antigen Rapid Test Kits [265]. - The company's operating loss increased by $634,808 to $13,841,204 in 2024, reflecting continued investment in growth strategy despite a gross loss in product sales [273]. - Net loss for 2024 was $14,863,161, an increase of $1,092,612 (8%) from $13,770,549 in 2023, attributed to increased non-exclusive use of certain patents related to VOC and POCT technologies [275]. Research and Development - Research and development (R&D) expenses increased by $1,096,535 (15%) to $8,413,923 in 2024, driven by increased staffing expenditures and co-research expenses [269]. - Clinical trial spending is expected to increase to advance VOC POCT and VELDONA drug candidates, alongside increased investment in R&D activities [290]. - The VOC co-development program achieved 79% accuracy in detecting 22 different volatile organic compounds (VOCs) in semiconductor factories [248]. Cash Flow and Financing - As of December 31, 2024, the company had available cash and cash equivalents of $3,892,919, up from $1,885,628 in 2023 [276]. - Net cash used in operating activities increased by $1,113,599, representing a 24% increase from 2023 to 2024, primarily due to a net loss for the year [278]. - Net cash used in investing activities rose to $125,292 in 2024 from $101,525 in 2023, a 23% increase attributed to higher refundable deposits and noncurrent assets [280]. - Cash provided by financing activities increased significantly by $3,102,073, reaching $8,025,746 in 2024, a 63% increase compared to $4,923,673 in 2023 [281]. - The company anticipates funding operations over the next twelve months through cash reserves, business revenues, and potential debt financing, with no assurance of achieving profitability [283]. - The company entered into an At The Market Offering Agreement on May 31, 2024, allowing for the issuance of shares based on market demand, with an aggregate offering price of $1,840,350 [286]. - The company plans to use net proceeds from the ATM offering to fund product development and general corporate purposes [287]. - As of December 31, 2024, no shares have been sold under the ATM Agreement [288]. Operational Expenses - Selling, general and administrative (SG&A) expenses slightly decreased by $239,860 (4%) to $5,395,415 in 2024, due to reduced professional expenses and public relations fees [271]. - The company may continue to incur operating losses in the near term as it grows its business, with expected increases in selling, general and administrative expenses, and R&D expenses [291]. Strategic Initiatives - The company signed a Memorandum of Understanding (MOU) with Taiwan Tanabe Seiyaku Co., Ltd. for the manufacturing and promotion of its Sjögren's syndrome drug based on VELDONA [246]. - The company plans to conduct clinical studies in Taiwan for VELDONA related to HIV-related oral warts and Sjögren's syndrome in 2025 [247]. Miscellaneous - The company had no off-balance sheet arrangements as of December 31, 2024 [299].

Core Viewpoint - Ainos has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price rule, allowing the company additional time to meet the required stock price threshold [1] Group 1 - The extension is a response to Ainos' stock price falling below the minimum bid price of $1 per share [1] - Ainos must achieve a closing bid price of at least $1 per share for a minimum of 10 consecutive trading days during the extension period [1] - The company has until May 6, 2024, to regain compliance with Nasdaq's listing requirements [1]

Core Viewpoint - Ainos, Inc. has signed a Memorandum of Understanding (MOU) with Taiwan Tanabe Seiyaku Co., Ltd. to advance the manufacturing and market promotion of its Sjögren's syndrome drug, VELDONA® [3][6]. Market Demand for Sjögren's Syndrome Treatment - Sjögren's syndrome is an autoimmune disease with a significant unmet need for effective treatments, affecting millions globally. The global market for Sjögren's syndrome treatment is projected to reach billions of dollars in the next five years due to increasing awareness and an aging population [4]. VELDONA®'s Clinical Progress and Success - VELDONA®, a low-dose oral interferon-alpha, has shown remarkable potential in clinical trials, significantly alleviating symptoms and improving quality of life for patients. The drug has demonstrated strong tolerability and safety, laying a solid foundation for further large-scale global clinical trials [5]. Partnership with Taiwan Tanabe Seiyaku - Taiwan Tanabe Seiyaku brings extensive pharmaceutical development and market expansion experience to the partnership. The collaboration will focus on the manufacturing and promotion of VELDONA® to meet market demand, with specific details to be clarified under the MOU [6]. Global Market Impact and Future Outlook - The collaboration is expected to accelerate the global introduction of VELDONA®, ensuring timely access for patients. As more clinical data is collected, demand for VELDONA® is anticipated to solidify its position as a leading treatment for Sjögren's syndrome, potentially opening opportunities in other autoimmune diseases [7]. Ainos' Future Vision - Ainos is committed to driving medical innovation and addressing unmet medical needs globally. The partnership with Taiwan Tanabe Seiyaku is a significant milestone in Ainos' global strategy, focusing on developing breakthrough therapies to improve patient quality of life [8].

Revenue Performance - The company reported nil revenue in Q3 2024, down from $24,489 in Q3 2023, due to the cessation of Ainos COVID-19 antigen rapid test kit sales and offset by sales returns of VELDONA Pet[125]. - Revenues for the first nine months of 2024 were $20,729, a decrease of $81,479 (80%) from $102,208 in the same period of 2023[137]. Expenses - Research and Development (R&D) expenses increased by $311,979 (18%) to $2,022,244 in Q3 2024, driven by co-research and staffing expenditures[128]. - Selling, General and Administrative (SG&A) expenses rose by $113,741 (13%) to $1,015,758 in Q3 2024, attributed to increased staffing and professional expenses[131]. - The Company's operating loss increased by $362,883 (14%) to $3,038,549 in Q3 2024 from $2,675,666 in Q3 2023[133]. - Research and development (R&D) expenses increased by $1,005,313 (20%) to $6,085,648 in the first nine months of 2024 from $5,080,335 in the same period of 2023[141]. - Selling, general and administrative (SG&A) expenses rose by $807,425 (35%) to $3,090,056 in the first nine months of 2024 compared to $2,282,631 in the same period of 2023[143]. Net Loss - The company incurred a net loss of $3,699,317 in Q3 2024, compared to a net loss of $2,975,846 in Q3 2023, reflecting a 24% increase in losses[124]. - Net loss for Q3 2024 was $3,699,317, reflecting a $723,471 (24%) increase compared to $2,975,846 in Q3 2023[135]. - Net loss for the first nine months of 2024 was $10,209,149, representing a $2,363,101 (30%) increase from $7,846,048 in the first nine months of 2023[149]. Cash Flow - As of September 30, 2024, the company had available cash and cash equivalents of $5,156,606, with plans to raise additional capital to fund operations[120]. - Cash used in operating activities increased by $1,622,282 to $4,944,036 in the first nine months of 2024 compared to $3,321,754 in the same period of 2023[151]. - Cash provided by financing activities increased by $4,271,772 to $8,295,746 in the first nine months of 2024 from $4,023,974 in the same period of 2023[153]. Clinical and Product Development - The company has initiated clinical studies for HIV oral warts and Sjögren's syndrome in Taiwan, with the U.S. FDA granting orphan drug designation for the VELDONA formulation[114]. - The company is developing a next-generation Ainos Flora device for at-home testing, utilizing compute unified device architecture (CUDA) for enhanced performance[114]. - The company has licensed additional patents to strengthen its AI Nose and POCT technologies, including a patent for treating coronavirus infection[119]. - The company expects to increase spending on clinical trials and R&D activities in the near term to advance its VOC POCT and VELDONA drug candidates[156]. Strategic Goals - The company aims to create multiple revenue streams through commercialization of its product portfolio and strategic partnerships[118].